TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01344148
Drug: INH RIF Rifb PZA EMB AZT 3TC D4T EFV
Normalized name: zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The first cohort study is the patients begin HAART after anti-TB therapy 2 weeks,and the second cohort is after 8 weeks begin HAART. Anti-TB therapy program is 2HREZ-4HRifb. And the first line of HAART plan is AZT+3TC+EFV and the second line plan is D4T+3TC+EFV.If begin with HAART and the RIF will change to Rifb.
Study: NCT01652313
Drug: Rasagiline
Normalized name: Rasagiline
DrugBank: Rasagiline (DB01367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 mg/day, tablets for 7 days, orally
Study: NCT00751478
Drug: ALO-01
Normalized name: aloe polysaccharide 0.01 MG/MG
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALO-01 capsules
Study: NCT00751478
Drug: MSIR
Normalized name: MSIR
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: immediate release morphine sulfate
Study: NCT00503490
Drug: MP-376 (Levofloxacin solution for Inhalation)
Normalized name: 6 MP
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40, 80, 120mg RDD
Study: NCT01838993
Drug: Lidocaine inhalation
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine inhalation before intubation
Study: NCT01641575
Drug: CO-1.01 and Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CO-1.01 administered over 30 minutes followed by 75 mg/ml Cisplatin over 2 hours (both intravenous) on C1D1. CO-1.01 administered intravenously over 30 minutes on C1D8.
Study: NCT00976456
Drug: Bevacizumab + Pemetrexed
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab 7,5 mg/kg i.v. over 60 min every 3 weeks plus pemetrexed 500 mg/m2 i.v. on D1 over 10 minutes every 3 weeks
Study: NCT00976456
Drug: Bevacizumab + Pemetrexed + Carboplatin
Normalized name: Carboplatin
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab 7,5 mg/kg i.v. over 60 min every 3 weeks plus pemetrexed 500 mg/m2 i.v. on D1 over 10 minutes and carboplatin AUC 5 on D1 every 3 weeks
Study: NCT02169648
Drug: ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: intravitreal injection of 0.50 mg (0.05ml) ranibizumab monthly as needed.
Study: NCT00583219
Drug: Botulinum-A toxin
Normalized name: Botulinum A neurotoxin
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: A simple bladder catheterization in the office with a standard urinary catheter and instill the Botulinum-A toxin/DMSO solution.
Study: NCT00583219
Drug: Dimethyl sulfoxide (DMSO)
Normalized name: Dimethyl Sulfoxide
DrugBank: Dimethyl sulfoxide (DB01093)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects received 50 cc of DMSO in an aqueous solution for intravesical instillation with botulinum-A toxin. Each cc contained 0.54 gm DMSO.
Study: NCT00854360
Drug: Beclomethasone dipropionate HFA Nasal Aerosol
Normalized name: beclomethasone dipropionate Nasal Product
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate (BDP) Hydrofluoroalkane (HFA) Nasal Aerosol
Study: NCT02949011
Drug: Baloxavir Marboxil
Normalized name: Baloxavir Marboxil
DrugBank: Baloxavir marboxil (DB13997)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tablets taken orally
Study: NCT02949011
Drug: Placebo to Baloxavir Marboxil
DrugBank: Baloxavir marboxil (DB13997)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Matching tablets taken orally
Study: NCT02949011
Drug: Oseltamivir
Normalized name: Oseltamivir
DrugBank: Oseltamivir (DB00198)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsules taken orally
Study: NCT02949011
Drug: Placebo to Oseltamivir
DrugBank: Oseltamivir (DB00198)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Matching placebo capsules taken orally
Study: NCT03307720
Drug: Human chorionic gonadotropin
Normalized name: human chorionic gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of Human chorionic gonadotropin (HCG) 250 IU subcutaneously , 36 hours before ovum pick-up in IVF treatments.
Study: NCT04466540
Drug: Hydroxychloroquine
Normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine pharmaceutical form will be tablets of 400 mg.
Study: NCT01747941
Drug: PF-06305591
Normalized name: PF-06305591
DrugBank: PF-06305591 (DB12106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose, solution
Study: NCT02087475
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02087475
Drug: 5-fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03894085
Drug: Paroxetine
Normalized name: Paroxetine
DrugBank: Paroxetine (DB00715)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paroxetine treatment for 4 weeks usage:20-80mg Qd
Study: NCT00252954
Drug: Levetiracetam
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablets 2000-3000 mg per day
Study: NCT03130842
Drug: Sublingual alprazolam
Normalized name: Alprazolam
DrugBank: Alprazolam (DB00404)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients receive one dose of oral formulation of alprazolam 0.5 mg for sublingual-administered at least 30 minutes before the procedure.
Study: NCT03130842
Drug: Oral midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients receive one dose of intravenous formulation of alprazolam 7.5 mg for oral-administered (in syrup with apple juice) at least 30 minutes before the procedure.
Study: NCT03781674
Drug: progesterone 400mg
Normalized name: PROGESTERONE 400MG SUPP,VAG,KIT
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Women received vaginal progesterone suppositories in a dose of 400 mg daily beginning at 18-22 weeks gestational age
Study: NCT03781674
Drug: progesterone 200mg
Normalized name: PROGESTERONE 200MG CAP
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Women received vaginal progesterone suppositories in a dose of 200 mg daily beginning at 18-22 weeks gestational age
Study: NCT03781674
Drug: placebo to progesterone 200mg
Normalized name: progesterone 200 MG
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Women received placebo to vaginal progesterone 200 mg suppositories in a dose of (2 tablets) daily beginning at 18-22 weeks gestational age
Study: NCT03781674
Drug: placebo to progesterone 400mg
Normalized name: placebo 400 MG
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Women received placebo to vaginal progesterone 400 mg suppositories in a dose of (4 tablets) daily beginning at 18-22 weeks gestational age
Study: NCT01541371
Drug: Paliperidone ER
Normalized name: Paliperidone ER
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Paliperidone Extended Release (ER) 3 milligram (mg) or 6 mg or 9 mg or 12 mg oral (by mouth) tablets depending on Investigator's discretion once daily for 12 weeks.
Study: NCT01131052
Drug: Insulin Glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: glargine once a day
Study: NCT01131052
Drug: Insulin
Normalized name: Insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sliding scale regular insulin (SSRI) given before meals and at bedtime as needed
Study: NCT01131052
Drug: Insulin glulisine
Normalized name: Insulin Glulisine
DrugBank: Insulin glulisine (DB01309)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: glulisine given as needed before meals
Study: NCT03609424
Drug: PDR001, Imatinib
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: -Phase Ib part~: The standard 3+3 dose escalation scheme will be applied. DLTs will be evaluated during the first cycle (4 weeks).~PDR001 400mg, every 4 weeks, IV~Imatinib dose level -1 : 200mg, PO, QD Imatinib dose level 1 : 300mg, PO, QD Imatinib dose level 2 : 400mg, PO, QD~-Phase II part~* Recommended dose defined in phase Ib part will be tested
Study: NCT00034814
Drug: Talampanel
Normalized name: Talampanel
DrugBank: Talampanel (DB04982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-enzyme-inducing TLP 35mg TID
Study: NCT00034814
Drug: Talampanel
Normalized name: Talampanel
DrugBank: Talampanel (DB04982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzyme-inducing Talampanel 35 mg TID
Study: NCT00034814
Drug: Talampanel
Normalized name: Talampanel
DrugBank: Talampanel (DB04982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzyme-inducing TLP 50mg TID
Study: NCT00034814
Drug: Talampanel
Normalized name: Talampanel
DrugBank: Talampanel (DB04982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-enzyme-inducing TLP 25mg TID
Study: NCT00477984
Drug: alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: alcohol(0.02%, 0.05%, 0.08% and 0.10%) and placebo
Study: NCT01575574
Drug: GADOXETIC ACID
Normalized name: Gadoxetic acid
DrugBank: Gadoxetic acid (DB08884)
Approvals — FDA: no, EMA: no, PMDA: no
Description: all patients will have a magnetic resonance with gadobutrol as reference for diagnosis; in participants an additional magnetic resonance will be done with the new contrast agent to verify if the diagnostic can be done.
Study: NCT00208130
Drug: Topiramate
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00374647
Drug: mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00374647
Drug: sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00038532
Drug: Amprenavir/ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01366339
Drug: Oral methylnaltrexone
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00038532
Drug: Saquinavir/ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00038532
Drug: Efavirenz
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03232632
Drug: PET with 18 F-Flutemetamol
DrugBank: Flutemetamol (18F) (DB09151)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PET with 18 F-Flutemetamol (Vizamyl ®)
Study: NCT03475134
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine will be administered as an intravenous (IV) infusion for five days.
Study: NCT03475134
Drug: Interleukin-2
Normalized name: INTERLEUKIN-2
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: After TIL infusion, IL-2 (optional) will be started as a bolus administration every eight hours, for a maximum of eight doses.
Study: NCT00859833
Drug: Regadenoson
Normalized name: Regadenoson
DrugBank: Regadenoson (DB06213)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Myocardial perfusion reserve measured during regadenoson (0.4 mg/5 ml) bolus administration using quantitative perfusion MRI.
Study: NCT01390623
Drug: Ceftriaxone
Normalized name: Ceftriaxone
DrugBank: Ceftriaxone (DB01212)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be included by investigators or coinvestigateurs, the day of consultation in the emergency adult department in Clermont-Ferrand city.~The diagnosis of acute uncomplicated pyelonephritis is established in the emergency department based on the clinical, laboratory and imaging criteria.
Study: NCT02712788
Drug: Milrinone
Normalized name: Milrinone
DrugBank: Milrinone (DB00235)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03475134
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab will be administered for maximum 24 months as follows: first year: 240 mg every 2 weeks; second year: 480 mg every 4 weeks.
Study: NCT06231212
Drug: ECa 233
Normalized name: ecamsule
DrugBank: Ecamsule (DB09534)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intervention groups are separated into group A and group B. Group A takes capsules containing 250 mg of ECa 233 and group B takes capsules containing 500 mg of ECa 233.
Study: NCT00936988
Drug: cinacalcet
Normalized name: Cinacalcet
DrugBank: Cinacalcet (DB01012)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subjects began open-label treatment with 30 mg cinacalcet twice daily (BID) at the start of the current study. The study consisted of 2 phases planned to total approximately 4¾ years: a 12-week dosetitration phase (visits at weeks 2, 3, 4, 6, 9, and 12) during which 1 possible dose increase of cinacalcet from 30 mg BID to 50 mg BID could occur at week 6, and a maintenance phase (week 12 to 234; visits approximately every 4 weeks until week 24 and approximately every 14 weeks thereafter) during which doses also could be titrated. After July 2004, because of a change in dose strengths, the daily doses used in the study were 30 and 60 mg BID with the option to reduce to 30 mg once daily (QD), if necessary. Ongoing subjects receiving 50 mg BID were switched at that time to 60 mg BID.
Study: NCT03619681
Drug: KN026
Normalized name: ANTI-HER2 BSAB KN026
DrugBank: Anbenitamab (DB18411)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient will be intravenously administrated with one dose of KN026. dosing interval may be adjusted during the study based on emerging data from this trial and/or from other trial.
Study: NCT01146145
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous morphine titration combined to ketamine
Study: NCT01415752
Drug: bendamustine hydrochloride
Normalized name: Bendamustine Hydrochloride
DrugBank: Bendamustine (DB06769)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01415752
Drug: bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV or SC
Study: NCT01415752
Drug: lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT03894891
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab is a type of immunotherapy.
Study: NCT03894891
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin is a chemotherapy drug.
Study: NCT03894891
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel is a chemotherapy drug.
Study: NCT01287494
Drug: Sertraline
Normalized name: Sertraline
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dosage form: Capsule dosage: 50-200mg/d frequency: once per day duration: 16 weeks
Study: NCT01378143
Drug: OCZ103-OS [pentamidine bis(2-hydroxyethanesulfonate)], mFOLFOX6 or FOLFIRI
DrugBank: Pentamidine (DB00738)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: OCZ103-OS is given in combination with Chemotherapy each cycle
Study: NCT04509258
Drug: N-acetyl cysteine
Normalized name: N-Acetyl Cysteine
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: a drug which can have an off label use as an antidot for aluminium phosphide poisoning in addition to sodium bicarbonate and ondansetron as standard of care
Study: NCT04509258
Drug: medicated paraffin oil
Normalized name: Paraffin
DrugBank: C11-12 isoparaffin (DB11329)
Approvals — FDA: no, EMA: no, PMDA: no
Description: refined mixture of liquid hydrocarbons which used as laxative and is suggested to reduce absorption of aluminium phosphide if taken within two hours of administration of the toxin in addition to sodium bicarbonate and ondansetron as standard of care
Study: NCT00003573
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01953744
Drug: Fluconazole
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluconazole is presented in 150mg capsules and will be administered by oral route at a dosage of 6-8mg/kg/day during 28 days.
Study: NCT01953744
Drug: Meglumine Antimoniate
Normalized name: meglumine antimoniate
DrugBank: Meglumine antimoniate (DB13732)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meglumine Antimoniate will be administered as the standard treatment for cutaneous leishmaniasis by intravenous route at a dosage of 20mg/kg/day, during 20 days.
Study: NCT02099682
Drug: Lansoprazole
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lansoprazole Capsules 15/ OD Tablets
Study: NCT02188173
Drug: dexamethasone 700 ㎍ intravitreal implant
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients who receive dexamethasone 700 ㎍ (OZURDEX®) intravitreal implant treatment for Diabetic Macular Edema. All decisions regarding treatment are made at the sole discretion of the treating physician in accordance with their usual practices.
Study: NCT00649103
Drug: Quinapril Hydrochloride Tablets 40 mg
Normalized name: Quinapril Hydrochloride
DrugBank: Quinapril (DB00881)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40mg, single dose fasting
Study: NCT00159094
Drug: Doxil and Vinorelbine
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00510276
Drug: Atomoxetine hydrochloride
Normalized name: Atomoxetine Hydrochloride
DrugBank: Atomoxetine (DB00289)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20-50 mg, twice a day per by mouth for 12 weeks, followed by up to an additional 12 weeks
Study: NCT00003573
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003573
Drug: vincristine sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03695510
Drug: Afatinib Oral Tablet
Normalized name: afatinib Oral Tablet
DrugBank: Afatinib (DB08916)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 40mg oral, daily, continuously
Study: NCT03695510
Drug: Pembrolizumab Injection
Normalized name: pembrolizumab Injection
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 200mg, intra-venous injection, every 3 weeks, for 35 cycles
Study: NCT03063658
Drug: Paracetamol
Normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The first dose of 1 gr intravenous paracetamol will be administered preoperatively and the remaining three doses will be given each six hours in the early postoperative period.
Study: NCT01440335
Drug: Oral R,R'-Fenoterol
DrugBank: Fenoterol (DB01288)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01440335
Drug: Oral Racemic Fenoterol
Normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00441792
Drug: Etomidate
Normalized name: Etomidate
DrugBank: Etomidate (DB00292)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Etomidate at induction dose based on weight
Study: NCT00441792
Drug: midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam at induction dose based on weight
Study: NCT04509258
Drug: Sodium Bicarbonate Powder and ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: standard of care for treatment of aluminuim phosphide is provided for patients poisoned with aluminuim phosphide
Study: NCT03404180
Drug: Intravenous Sedatives
Normalized name: Sed-Max
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous sedation using propofol or dexmedetomidine will be administered.
Study: NCT00005830
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00495170
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2 area under curve (AUC) by vein Weekly
Study: NCT02286063
Drug: Ambulatory Oxygen
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The IMP investigated in this study is medical oxygen (PL 15929/005), manufactured by Air Liquide Ltd. UK. Oxygen is a colourless, odourless gas with molecular weight 32, a boiling point of 183.1°C (at 1 bar) and a density of 1.355 kg/m3 (at 15°C and 1013mb).~Oxygen is present in the atmosphere at 21% and is an absolute necessity for life. Each of the four oxygen companies across the UK provide a light and a standard weight oxygen cylinder. Ambulatory Oxygen will be given to the Oxygen arm.
Study: NCT03810976
Drug: Eribulin, gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Elibulin 1.4mg/m2 Intravenous for 5minutes. Day 1\& Day 8 every 3 weeks Gemcitabine 1000mg/m2 intraveoust for 30 minutes, Day 1\& Day 8 every 3 weeks
Study: NCT03780257
Drug: QR-421a
Normalized name: mannitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: RNA antisense oligonucleotide for intravitreal injection
Study: NCT02441894
Drug: CABAZITAXEL XRP6258
Normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form:solution Route of administration: intravenous
Study: NCT02441894
Drug: Dexchlorpheniramine or Diphenhydramine
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form:tablet, powder, or solution Route of administration: oral, intravenous or intramuscular
Study: NCT02441894
Drug: Ranitidine
Normalized name: Ranitidine
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form:tablet or solution Route of administration: oral, intravenous or intramuscular
Study: NCT02441894
Drug: Metoclopramide, Granisetron, or Ondansetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form:tablet, powder, jelly, or solution Route of administration: oral, intravenous or intramuscular
Study: NCT02441894
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmaceutical form:tablet, capsule, or solution Route of administration: oral or intravenous
Study: NCT00659425
Drug: CAT-8015 (Moxetumomab Pasudotox)
Normalized name: Spotted cat
DrugBank: Channel catfish (DB15548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received intravenous infusion of 5 mcg/kg moxetumomab pasudotox (CAT-8015) without concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.